Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Provided By GlobeNewswire
Last update: Jan 28, 2025
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR T product.
Read more at globenewswire.com2.17
-0.08 (-3.77%)
Find more stocks in the Stock Screener
ALLO Latest News and Analysis
4 days ago - ChartmillTuesday's session: gap up and gap down stocksLet's have a look at the gap up and gap down stocks in today's session.
8 days ago - ChartmillFriday's session: top gainers and losersCurious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
8 days ago - ChartmillWhat's going on in today's sessionHere are the top movers in Friday's session, showcasing the stocks with significant price changes.
8 days ago - ChartmillFriday's session: gap up and gap down stocksIn today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down.
